Released Nov 9, 2017, after the close
10-Q filed Nov 9, 2017, 40 days after period end · 0001390478-17-000074
Q3 2017 · 10-Q
Revenue—
Net Income-$4.46M-$4.46M N/M vs Q3 2016N/M vs Q2 2017
EPS Diluted-$2.27-$2.27 no prior Q3 2016 on fileN/M vs Q2 2017
Operating Income-$4,462,000N/M
Operating Cash Flowderived-$2,395,000N/M
What the release said
The release
Same quarter
| Metric | Q3 2017 | Q3 2016 | Q3 2013 | Q3 2012 |
|---|---|---|---|---|
| Revenue | — | — | $2.17M | $2.17M |
| Net Income | -$4.46M | -$6.93M | -$6.93M | -$18.03M |
| EPS Diluted | -$2.27 | — | -$0.11 | -$0.09 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR